“Not all humans age biologically at the same rate,” says David Furman.
Credit: Simon Melov
Scientists at Stanford and the Buck Institute have found a way to predict an individual’s immunological decline as well as the likelihood of incurring age-associated diseases and becoming frail.
You’re as old as your immune system.
Investigators at the Stanford University School of Medicine and the Buck Institute for Research on Aging have built an inflammatory-aging clock that’s more accurate than the number of candles on your birthday cake in predicting how strong your immune system is, how soon you’ll become frail or whether you have unseen cardiovascular problems that could become clinical headaches a few years down the road.
In the process, the scientists fingered a bloodborne substance whose abundance may accelerate cardiovascular aging.
The story of the clock’s creation published July 12 in Nature Aging.
“Every year, the calendar tells us we’re a year older,” said David Furman, PhD, the study’s senior author. “But not all humans age biologically at the same rate. You see this in the clinic — some older people are extremely disease-prone, while others are the picture of health.”
This divergence, Furman said, traces in large part to differing rates at which people’s immune systems decline. The immune system — a carefully coordinated collection of cells, substances and strategies with which evolution has equipped us to deal with threats such as injuries or invasions by microbial pathogens — excels at mounting a quick, intense, localized, short-term, resist-and-repair response called acute inflammation. This “good inflammation” typically does its job, then wanes within days. (An example is that red, swollen finger you see when you have a splinter, and the rapid healing that follows.)
As we grow older, a low-grade, constant, bodywide “bad inflammation” begins to kick in. This systemic and chronic inflammation causes organ damage and promotes vulnerability to a who’s who of diseases spanning virtually every organ system in the body and including cancer, heart attacks, strokes, neurodegeneration and autoimmunity.
To date, there have been no metrics for accurately assessing individuals’ inflammatory status in a way that could predict these clinical problems and point to ways of addressing them or staving them off, Furman said. But now, he said, the study has produced a single-number quantitative measure that appears to do just that.
Furman directs the Stanford 1000 Immunomes Project and is a visiting scholar at Stanford’s Institute for Immunity, Transplantation and Infection. In addition, he’s an associate professor at the Novato, California-based Buck Institute for Research on Aging and director of the Artificial Intelligence Platform at the same institute.
Lead authors of the study are Nazish Sayed, MD, PhD, assistant professor of vascular surgery at Stanford, and Yingxiang Huang, PhD, senior data scientist at the Buck Institute.
For the 1000 Immunomes Project, blood samples were drawn from 1,001 healthy people ages 8-96 between 2009 and 2016. The samples were subjected to a barrage of analytical procedures determining levels of immune-signaling proteins called cytokines, the activation status of numerous immune-cell types in responses to various stimuli, and the overall activity levels of thousands of genes in each of those cells.
The new study employed artificial intelligence to boil all this data down to a composite the researchers refer to as an inflammatory clock. The strongest predictors of inflammatory age, they found, were a set of about 50 immune-signaling proteins called cytokines. Levels of those, massaged by a complex algorithm, were sufficient to generate a single-number inflammatory score that tracked well with a person’s immunological response and the likelihood of incurring any of a variety of aging-related diseases.
In 2017, the scientists assessed nearly 30 1000 Immunomes Project participants ages 65 or older whose blood had been drawn in 2010. They measured the participants’ speed at getting up from a chair and walking a fixed distance and, through a questionnaire, their ability to live independently (“Can you walk by yourself?” “Do you need help getting dressed?”). Inflammatory age proved superior to chronological age in predicting frailty seven years later.
Next, Furman and his colleagues obtained blood samples from an ongoing study of exceptionally long-lived people in Bologna, Italy, and compared the inflammatory ages of 29 such people (all but one a centenarian) with those of 18 50- to 79-year-olds. The older people had inflammatory ages averaging 40 years less than their calendar age. One, a 105-year-old man, had an inflammatory age of 25, Furman said.
To further assess inflammatory age’s effect on mortality, Furman’s team turned to the Framingham Study, which has been tracking health outcomes in thousands of individuals since 1948. The Framingham study lacked sufficient data on bloodborne-protein levels, but the genes whose activity levels largely dictate the production of the inflammatory clock’s cytokines are well known. The researchers measured those cytokine-encoding genes’ activity levels in Framingham subjects’ cells. This proxy for cytokine levels significantly correlated with all-cause mortality among the Framingham participants.
A key substance
The scientists observed that blood levels of one substance, CXCL9, contributed more powerfully than any other clock component to the inflammatory-age score. They found that levels of CXCL9, a cytokine secreted by certain immune cells to attract other immune cells to a site of an infection, begin to rise precipitously after age 60, on average.
Among a new cohort of 97 25- to 90-year-old individuals selected from the 1000 Immunomes Project for their apparently excellent health, with no signs of any disease, the investigators looked for subtle signs of cardiovascular deterioration. Using a sensitive test of arterial stiffness, which conveys heightened risk for strokes, heart attacks and kidney failure, they tied high inflammatory-age scores — and high CXCL9 levels — to unexpected arterial stiffness and another portent of untoward cardiac consequences: excessive thickness of the wall of the heart’s main pumping station, the left ventricle.
CXCL9 has been implicated in cardiovascular disease. A series of experiments in laboratory dishware showed that CXCL9 is secreted not only by immune cells but by endothelial cells — the main components of blood-vessel walls. The researchers showed that advanced age both correlates with a significant increase in endothelial cells’ CXCL9 levels and diminishes endothelial cells’ ability to form microvascular networks, to dilate and to contract.
But in laboratory experiments conducted on tissue from mice and on human cells, reducing CXCL9 levels restored youthful endothelial-cell function, suggesting that CXCL9 directly contributes to those cells’ dysfunction and that inhibiting it could prove effective in reducing susceptible individuals’ risk of cardiovascular disease.
“Our inflammatory aging clock’s ability to detect subclinical accelerated cardiovascular aging hints at its potential clinical impact,” Furman said. “All disorders are treated best when they’re treated early.”
Original Article: Immune system “clock” predicts illness and mortality
More from: Stanford University School of Medicine | Buck Institute for Research on Aging | University of North Carolina | Technion-Israel Institute of Technology | Catholic University of Leuven | University of Bologna | University of Florence
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Immune system clock
- Novel subset of immune cells confers fast-acting and lasting protection against ischemic stroke
A unique subset of white blood cells confers fast-acting and lasting protection against ischemic stroke in mice, University of Pittsburgh neurologists and immunologists reported in the Journal of ...
- Is this the new CBD? Medicinal mushrooms could be the answer to your post-pandemic burnout
Medicinal mushroom supplements are the latest celebrity wellness trend, adored by the likes of Meghan Markle, Gwyneth Paltrow and Elle Macpherson, but does the science behind them stack up? We took a ...
- Singapore law society president pledges to ‘fight cancer until the clock runs out’
The president of the Law Society of Singapore has received sympathy and support from the profession after pledging to continue in the role despite undergoing an ‘aggressive treatment regime’ for ...
- AC Immune: Q2 Earnings Snapshot
AC Immune SA (ACIU) on Thursday reported a loss of $20.4 million in its second quarter. The 1015 Lausanne, Switzerland-based company said it had a loss of 24 cents per share.
- 'Until the clock runs out': Law Society president Adrian Tan reveals he has cancer, says will fight illness and continue his work
SINGAPORE: Law Society president Adrian Tan said on Thursday (Jul 28) that he was diagnosed with cancer in March, just months after he was elected to the post in January. Mr Tan, a partner and head of ...
Go deeper with Google Headlines on:
Immune system clock
Go deeper with Bing News on:
- With ‘bold experiment’ in drug pricing, Arcutis aims to stand out in plaque psoriasis
The FDA approved Arcutis Biotherapeutics drug Zoryve, a topical treatment for plaque psoriasis. With the decision, the company will proceed with a pricing strategy it believes will speed up insurance ...
- In The Age Of Misinformation, How Misleading Content Impacts Digital Advertising
In this guest post, Integral Ad Science’s ANZ country manager Jessica Miles (lead image), looks at how deceptive content and “fake” news could all be being funded by your digital advertising budget… ...
- Medical Trauma in Patients With IBD
Among over 600 patients who were hospitalized at least once, 55% said IBD symptoms or flares were a source of trauma, and 40% named hospitalizations as a source, reported Tiffany Taft, PsyD, MIS, of ...
- STELARA® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients ...
- COVID-19 Outcomes, Therapies in Immune-Mediated Inflammatory Disease
A large population study assessed risk for severe COVID-19 outcomes in people with immune-mediated inflammatory diseases using immune-modifying therapies.